SCHEMBL4439005

SCHEMBL4439005

O=C(O)c1ccc2c(c1)[nH]c(=O)n2C1CCN(CC(=O)N2CCC3(CC2)CC3)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
YEATS4 O95619 2/20 0.51
KCNH2 Q12809 2/20 0.51
PLD1 Q13393 11/20 0.48
PLD2 O14939 11/20 0.48
MLLT3 P42568 1/20 0.47
MLLT1 Q03111 1/20 0.47
YEATS2 Q9ULM3 1/20 0.47
AKT1 P31749 2/20 0.46
AKT2 P31751 2/20 0.46
AKT3 Q9Y243 1/20 0.46
DRD2 P14416 2/20 0.45
HTR1A P08908 1/20 0.45
ADRA2A P08913 1/20 0.45
HTR2A P28223 1/20 0.45
SLC6A4 P31645 1/20 0.45
DRD3 P35462 1/20 0.45
HSD11B1 P28845 1/20 0.45
USP2 O75604 1/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4437932 0.91 YEATS4 (0.52) YEATS4KCNH2PLD1PLD2MLLT3
SCHEMBL4436453 0.90 YEATS4 (0.53) YEATS4KCNH2PLD1PLD2MLLT3
SCHEMBL4435708 0.89 PLD1 (0.52) YEATS4KCNH2PLD1PLD2MLLT3
SCHEMBL4438587 0.87 YEATS4 (0.51) YEATS4KCNH2PLD1PLD2MLLT3
SCHEMBL4566119 0.85 YEATS4 (0.59) YEATS4KCNH2PLD1PLD2MLLT3
SCHEMBL4440295 0.85 YEATS4 (0.61) YEATS4KCNH2PLD1PLD2MLLT3
SCHEMBL4435287 0.84 YEATS4 (0.51) YEATS4KCNH2PLD1PLD2MLLT3
SCHEMBL4991406 0.84 OPRM1 (0.58) YEATS4KCNH2PLD1PLD2MLLT3
SCHEMBL4446718 0.83 OPRM1 (0.42) KCNH2PLD1PLD2HSD11B1CHRM1
SCHEMBL4445890 0.82 YEATS4 (0.49) YEATS4KCNH2PLD1PLD2MLLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121656-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE Pfizer Products Inc. (US) 2009-11-25 EP claimed
US-20080287479-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE PFIZER INC 2008-11-20 US claimed
WO-2008084300-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE PFIZER PRODUCTS INC. (US) 2008-07-17 WO claimed
EP-2121656-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE Pfizer Products Inc. (US) 2009-11-25 EP disclosed
US-20080287479-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE PFIZER INC 2008-11-20 US disclosed
WO-2008084300-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE PFIZER PRODUCTS INC. (US) 2008-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287479-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE SPTLC1, SPTLC2, CPT1A YEATS4 1467/4885KCNH2 4650/4885PLD1 351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.